XNASCGTX
Market cap28mUSD
Jan 17, Last price
0.68USD
1D
-1.80%
1Q
37.90%
IPO
-94.46%
Name
Cognition Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-26m
L
CFO
-16m
L-13.57%
Earnings
Jun 06, 2025
Profile
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 50,976 | 43,786 | |||
Unusual Expense (Income) | |||||
NOPBT | (50,976) | (43,786) | |||
NOPBT Margin | |||||
Operating Taxes | (22,154) | ||||
Tax Rate | |||||
NOPAT | (50,976) | (21,632) | |||
Net income | (25,788) -3,506.61% | 757 -107.36% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 5,332 | 5,324 | |||
BB yield | -9.60% | -8.74% | |||
| Debt | |||||
Debt current | 348 | 783 | |||
Long-term debt | 1,734 | 1,539 | |||
Deferred revenue | 1,686 | ||||
Other long-term liabilities | (520) | 695 | |||
Net debt | (27,840) | (39,240) | |||
| Cash flow | |||||
Cash from operating activities | (16,018) | (18,533) | |||
CAPEX | (147) | (171) | |||
Cash from investing activities | (147) | (171) | |||
Cash from financing activities | 4,521 | 5,546 | |||
FCF | (50,871) | (22,533) | |||
| Balance | |||||
Cash | 29,922 | 41,562 | |||
Long term investments | |||||
Excess cash | 29,922 | 41,562 | |||
Stockholders' equity | (141,352) | (115,571) | |||
Invested Capital | 166,694 | 159,679 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 30,029 | 28,992 | |||
Price | 1.85 -11.90% | 2.10 -66.77% | |||
Market cap | 55,554 -8.75% | 60,882 -56.67% | |||
EV | 27,714 | 21,642 | |||
EBITDA | (50,724) | (43,551) | |||
EV/EBITDA | |||||
Interest | 28 | ||||
Interest/NOPBT | |||||